WO1993019775A1 - Administration de liposomes contenant des peptides ou des proteines comportant des determinants antigeniques de ctl de proteines vih - Google Patents
Administration de liposomes contenant des peptides ou des proteines comportant des determinants antigeniques de ctl de proteines vih Download PDFInfo
- Publication number
- WO1993019775A1 WO1993019775A1 PCT/US1993/002978 US9302978W WO9319775A1 WO 1993019775 A1 WO1993019775 A1 WO 1993019775A1 US 9302978 W US9302978 W US 9302978W WO 9319775 A1 WO9319775 A1 WO 9319775A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- protein
- hiv
- liposomes
- proteins
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 117
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 75
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 75
- 239000002502 liposome Substances 0.000 title abstract description 65
- 102000004196 processed proteins & peptides Human genes 0.000 title description 25
- 230000004044 response Effects 0.000 claims abstract description 21
- 150000002632 lipids Chemical class 0.000 claims abstract description 16
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 9
- 230000001939 inductive effect Effects 0.000 claims abstract description 6
- 102100034353 Integrase Human genes 0.000 claims description 10
- 108010078428 env Gene Products Proteins 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 description 60
- 241000725303 Human immunodeficiency virus Species 0.000 description 36
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 33
- 239000000562 conjugate Substances 0.000 description 21
- 229940037003 alum Drugs 0.000 description 18
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 10
- 239000000863 peptide conjugate Substances 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 108010058846 Ovalbumin Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229940092253 ovalbumin Drugs 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 108010015792 glycyllysine Proteins 0.000 description 4
- -1 p-methylbenzyl Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IHMCQESUJVZTKW-UBHSHLNASA-N Ala-Phe-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 IHMCQESUJVZTKW-UBHSHLNASA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HQZGVYJBRSISDT-BQBZGAKWSA-N Cys-Gly-Arg Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQZGVYJBRSISDT-BQBZGAKWSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 2
- BSWLQVGEVFYGIM-ZPFDUUQYSA-N Ile-Gln-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N BSWLQVGEVFYGIM-ZPFDUUQYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- URPSJRMWHQTARR-MBLNEYKQSA-N Thr-Ile-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O URPSJRMWHQTARR-MBLNEYKQSA-N 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 1
- YQGZIRIYGHNSQO-ZPFDUUQYSA-N Arg-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YQGZIRIYGHNSQO-ZPFDUUQYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010039334 HIV Envelope Protein gp120 Proteins 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- This invention relates to the induction of a T-cell
- this invention relates to the induction of a CTL response against HIV by administering liposomes containing peptides or proteins including CTL epitopes of HIV proteins.
- CMI Cell-mediated immunity
- HIV human immunodeficiency virus
- AIDS virus HIV vaccines and/or therapies based on the generation of passive transfer of HIV-specific antibody in the absence of cell-mediated immunity have not yielded consistent protection in primates challenged with the HIV virus.
- immune responses to certain segments of the virus may be deleterious.
- Such problems associated with the development of vaccines against AIDS virus may be avoided by employing vaccines which include small regions of HIV proteins which are known to produce neutralizing antibody responses or cytotoxic T lymphocyte responses.
- a potential target for use in a vaccine against HIV is the HIV envelope, or env protein (also referred to as gp 120 or gp 160).
- the HIV env protein contains several hypervariable regions (or V regions), of which one region, the V3 loop, contains a peptide sequence that is important for the generation of humoral and cellular immune responses.
- the V3 loop which is defined by a disulfide bond, contains a principal neutralizing determinant (or PND), as antibodies specific for the V3 loop have been shown to neutralize HIV (Rusche, et al., PNAS, Vol. 85, pgs. 3198-3202 (1988); Goudsmit, et al., PNAS. Vol. 85, pgs.
- a method of inducing in an animal, a CTL response against HIV comprises administering to an animal lipid vesicles, or liposomes including at least one peptide or protein which includes at least one CTL epitope of an HIV
- the lipid vesicles, or liposomes are administered in an amount effective to induce in an animal a CTL response against HIV.
- liposomes including at least one peptide or protein which includes at least one CTL epitope of an HIV
- the peptide or protein which includes a CTL eptiope of an HIV protein may be encapsulated within the liposome, ..or may form a portion of the liposome wall, or may be bound to the liposome wall.
- the peptide or protein may be bound to the exterior or to the interior of the liposome wall.
- lipid vesicles including a peptide or protein which includes a CTL epitope of an HIV protein are administered to an animal, an increased CTL response in the animal against HIV is obtained.
- liposomes are taken up by macrophages, and the peptide contained within them can be presented to T cells or can enter the
- Peptides or proteins which include CTL epitopes of HIV proteins, and which may be included in the liposomes include, but are not limited to, HIV env (also known as gp 120 or gp 160); HIV-gp 41; HIV pol; HIV nef; HIV gag; HIV tat; HIV rev; HIV vif; HIV vpr; HIV vpu; and HIV vpx, or fragments or derivatives thereof.
- the peptide or protein is an HIV env protein or fragment or derivative thereof.
- the peptide or protein is the V3 loop of the HIV env protein gp 120, or a fragment or derivative thereof.
- the peptide or protein is the P18 peptide of the V3 loop of HIV-III-B env protein.
- P18 peptide has the following structural formula:
- the peptide or protein may, in one embodiment, be conjugated with a conjugate peptide or protein prior to being included in the liposome.
- the conjugate may be attached to the N-terminal or the C-terminal of the peptide or protein.
- conjugate peptides or proteins include, but are not limited to, ovalbumin.
- one or more amino acids be attached to the N-terminal or the C-terminal of the peptide or protein prior to attachment of the peptide or protein to the conjugate peptide or protein, and wherein the peptide or protein is attached to the conjugate peptide or protein via the cysteine residue.
- a cysteine residue or an amino acid chain having a cysteine residue at its N-terminus is attached to the N-terminal of the peptide or protein.
- a cysteine residue or an amino acid chain having a cysteine residue at its N-terminus is attached to the N-terminal of the peptide or protein.
- C-terminus is attached to the C-terminal of the peptide or protein.
- a Cys-Gly (CG) dipeptide is attached to the N-terminal of P18 peptide to form a peptide having the following structural formula:
- This peptide may then be attached to a conjugate peptide or protein, such as ovalbumin, to form a conjugate such as, for example, ovalbumin-Cys-Gly-P18 peptide.
- a conjugate peptide or protein such as ovalbumin
- such peptides or proteins having a cysteine -containing amino acid chain at the N-terrainus or C-terminus may be included in a liposome alone (without being attached to a conjugate peptide or protein) in order to induce a CTL response against HIV.
- Applicants have found that when a Cys-Gly-P18 peptide contained in a liposome is administered to an animal, that, in addition to a CTL response, an improved humoral immune response against HIV is generated as well. It is to be understood, however, that the scope of the present invention is not to be limited to any particular conjugate peptides or proteins, or to any particular cystein-containing amino acid chains which may be attached to the peptides or proteins of the present invention.
- the peptides or proteins employed in the present invention may be synthesized by means well-known in the art.
- the peptides or proteins may be synthesized on an automatic peptide synthesizer. (Merrifield, J. Am. Chem. Soc., Vol. 85, pg. 2149 (1963)).
- the peptides or proteins may be produced by genetic engineering techniques. For example, there may be provided DNA encoding a peptide or protein which includes a CTL epitope of an HIV protein. The DNA is placed in an appropriate expression vector, which is transformed into an appropriate organism which expresses the peptide or protein.
- the liposome which includes the peptide or protein may be formed by a variety of methods known to those skilled in the art.
- the liposome may be formed according to the methods of Alving, et al., Liposome Technology, Gregoriadis, ed., (CRC Press, Boca Raton, Florida) or Fries, et al., PNAS, Vol. 89, pgs. 358-362 (1992).
- the liposomes may be formed, for example, from one or more lipids and one or more sterols.
- Lipids which may be employed include, but are not limited to, phosphatidylcholine, phosphatidylglycerol, phosphatidylserine, spingomyelin,
- phosphatidylethanolaimine phosphatidylinositol
- phosphatidic acid phosphatidic acid
- cardiolysin phosphatidylethanolaimine
- Sterols which may be employed include cholesterol and lanosterol.
- the liposomes may further include lipid A or a lipopolysaccharide which, along with the above-mentioned lipids and sterols, also becomes incorporated in the liposome wall.
- the peptides or proteins may, in one embodiment, be encapsulated within the liposomes by a variety of means known to those skilled in the art.
- a lyophilized lipid film may be reconstituted with a buffer containing the peptides, or proteins, whereby a portion of the peptide or protein becomes encapsulated within the liposome during reconstitution.
- the present invention has been described with respect to encapsulation of the peptides or proteins within liposomes, it is to be understood that within the scope of the present invention, the peptides or proteins may form part of the liposome wall or may be attached to the liposome wall such that the peptide or protein is attached to the exterior or the
- composition for inducing in an animal a CTL response against HIV which comprises a lipid vesicle including least one peptide or protein including at least one CTL epitope of an HIV protein.
- the lipid vesicle, or liposome, and the peptide or protein may be those hereinabove described.
- the liposomes which include the peptide or protein which includes a CTL epitope of an HIV protein may be employed in a composition, such as a vaccine, for inducing in an animal a CTL response against HIV.
- the vaccine may be administered to a human or non-human animal.
- the liposomes may be administered in conjunction with a suitable pharmaceutical carrier.
- Vehicles for vaccines are well known in the art and the selection of a suitable vehicle is deemed to be within the scope of those skilled in the art from the teachings contained herein. The selection of a suitable vehicle is also dependent upon the manner in which the vaccine is to be administered. Alternatively, because liposomes possess adjuvant properties, the liposomes may be administered without a carrier and instead may be administered in water alone.
- the vaccine may be in the form of an injectable dose and may be administered intramuscularly, intravenously, orally, intradermally, or by subcutaneous administration.
- the peptide or protein may be administered to an average human adult in an amount of from about 1 microgram to about 1,500 micrograms, preferably from about 10 micrograms to about 1,000 micrograms.
- the peptide may be administered for example at monthly intervals for a period of time of about three months. It is to be understood, however, that the scope of the present invention is not to be limited to any particular dosage levels or intervals of administration.
- Synthetic P18 peptide (SEQ ID NO:1); or P18 peptide having Cys-Gly chain attached to its N-terminus (SEQ ID NO:2), also sometimes hereinafter referred to as CG-P18 was synthesized by using the stepwise solid phase approach of Merrifield, J. Am.
- acylating species were used as the acylating species for all amino acids except asparagine, glutamine, arginine, and histidine.
- Ovalbumin (5 mg. or 100 nmole) was dissolved in 1 ml PBS, pH 6.8. To this solution was added 3 mg (10 ⁇ mole) m-male- imidobenzoyl-N-hydroxysuccinimide ester (MBS) dissolved in 300 ml of synthesis grade dimethyiformamide (DMF). The mixture was allowed to react for one hour at room temperature with gentle mixing. At the end of one hour reaction time, the entire mixture was desalted over a 1cm x 20 cm column packed with Sephadex G-50 equilibrated with 0.1M phosphate buffer, pH 6.0. The eluant was monitored for absorbance at 280 mm, and the derivatized fraction of maleimidobenzyl ovalbumin (OVA-MB) was collected in the void volume (V ).
- V void volume
- Cysteine-containing peptides (3 to 5 mg) were dissolved in 1 ml cold 0.1M sodium borate buffer, pH 9.1. To this was added 100 ml of a 0.1M sodium borohydride solution. The reduction was permitted to proceed for 15 min at 4oC. After 15 min excess reducing agent was destroyed by acidifying with 6N hydrochloric acid. Following this the solution containing reduced peptide (either P18 or CG-P18) was returned to neutral pH (pH 6-7) with sodium hydroxide. The reduced peptide was slowly added with stirring to the derivatized protein fraction (OVA-MB) prepared above. This mixture was reacted overnight at room temperature. The conjugation reaction mixture was extensively dialyzed (MWCO 12,000-14,000 daltons) against water at 4°C to remove excess peptide and buffer salts.
- OVA-MB derivatized protein fraction
- the number of moles of peptide conjugated per mole OVA was determined by amino acid analysis.
- the OVA-MB-peptide conjugates and OVA were hydrolyzed separately with 100 ul constant boiling (6N) HCl for 2 hours at 150°C.
- the hydrolyzates were then dried in vacuo in the presence of potassium hydroxide.
- the dried-down samples were then resuspended and applied to a Beckman "System Gold" analyzer for determination of the amino acid content. By examining and comparing the ratio of amino acids determined for both the OVA and OVA-MB-peptide the extent of crosslinking was evaluated.
- Liposomes were prepared as taught by Alving, et al. (in
- the chloroform was removed with a rotary evaporator and the lipid film further dried in a vacuum dessicator.
- the resultant lipid film was hydrated with sterile water to a final phospholipid concentration of 50-200 mM and then lyophilized. After lyophilization, liposomes were reconstituted to a
- PBS phosphate-buffered saline, pH 7.4, (PBS) containing peptide P18, CG-P18, or P18 peptide conjugate.
- PBS phosphate-buffered saline, pH 7.4,
- Unencapsulated P18 peptide, CG-P18, or peptide conjugate was removed by washing the liposomes with PBS and washed pellets were resuspended in PBS to a phospholipid concentration of 100-200 mM.
- the encapsulated peptide or peptide conjugate was determined and the final
- liposome preparation was diluted appropriately according to the concentration of peptide or peptide conjugate required per injection. Concentration of the peptide or peptide conjugate was measured by hydrolyzing a sample of the liposomes in 6N HCl for 2 hours and examining by amino acid analysis as described above.
- Preparations for immunization contained peptide (P18 or CG-P18) alone or conjugated to ovalbumin.
- Peptide was
- the non-encapsulated peptide or peptide conjugate was administered in PBS with no adjuvant, in PBS emulsified in complete Freund's adjuvant (CFA) for priming, and in incomplete Freund's adjuvant (IFA) for boosting, or adsorbed onto 1.5 mg of aluminum hydroxide (alum).
- CFA complete Freund's adjuvant
- IFA incomplete Freund's adjuvant
- Peptide or peptide conjugate encapsulated in liposomes was administered either in liposomes alone or in liposomes adsorbed with 1.5 mg of alum.
- mice (4 per group) were given primary immunizations of peptide or peptide conjugate intraperitoneally, and boosting intraperitoneal immunizations 3 weeks later (for the peptide-protein conjugate) or 3 and 11 weeks later (for the peptides).
- Immulon R flat-bottom plates were coated overnight with 250 ng/well of P18. After washing and blocking with PBS containing 3% dry milk and 0.1% Tween-20, various dilutions of sera diluted in PBS containing 1% goat serum and 0.1% Tween-20 were added and incubated for 1 hour. The plates were washed and goat anti-mouse IgG conjugated to horseradish peroxidase was added and incubated for 1 hour. After washing, substrate solution was added and allowed to develop for 30 min. Readings were taken at a
- mice immunized with OVA-CG-P18 were tested at 3, 5, 7, and 17 weeks after the initial immunization.
- mice immunized with P18 peptide or CG-P18 were tested at 7 weeks after the initial immunization.
- the peptides had been administered without adjuvant, in CFA/IFA, in alum, in liposomes, in liposomes in alum, in liposomes with lipid A, or in liposomes with lipid A in alum.
- the anti-P18 titers are given in Table II below.
- CTL cytolytic
- Spleens from mice immunized with OVA-CG-P18, P18, or CG-P18 were taken and disrupted to make a single cell suspension. Spleen cells were washed and cultured in 25 cm 2 flasks at 5 ⁇ 10 7 cells/flask in a volume of 10 ml. Syngeneic P815 cells were pulsed with 50 ug of P18 for 40 min and then mitomycin C treated for 40 min and added to the flasks at 5 ⁇ 10 6 cells/flask.
- effector cells were added to 96 well microtiter plates at 5 ⁇ 10 5 , 2.5 ⁇ 10 5 , and 6.25 ⁇ 10 4 cells/well.
- P815 cells that were pulsed with 35 ug P18 or left unpulsed were loaded with 200 uCi of 51 Cr for 2 hrs. and added to the cultures at 5 ⁇ 10 3 cells/well.
- P815 cells that were loaded with 51 Cr were cultured alone (to determine spontaneous release) or with 10% sodium dodecyl sulfate (to determine total release). Cells were cultured for 4 hrs. and the supernatants were harvested and counted to determine 51 Cr release. Percent lysis was determined by the following equation:
- Figure 1 shows the CTL activity of spleens from mice immunize with OVA-CG-P18 conjugate, which was administered as described in Example 5. The spleens were taken 14 weeks after the initial immunization. As shown in Figure 1, maximal CTL response was obtained when the OVA-CG-F18 conjugate was encapsulated in
- liposomes with lipid A without adsorption of the liposomes to alum.
- FIG. 2 shows the CTL activity of spleens from mice immunize with Pl ⁇ or CG-P18, which was administered as described in Example 5. The spleens were taken 18 weeks after the initial immunization As shown in Figure 2, mice that received peptide encapsulated in lipsomes containing lipid A were able to mount a CTL response to P18.
- ADDRESSEE Carella, Byrne, Bain,
- NAME/KEY P18 peptide derivative
- xi SEQUENCE DESCRIPTION: SEQ ID NO: 2: Cys Gly Arg Ile Gln Arg Gly Pro Gly Arg
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un procédé permet d'induire chez l'animal une réaction des lymphocytes T cytotoxiques (CTL) contre le VIH. Il comprend l'administration à cet animal de vésicules lipidiques (des liposomes par exemple) qui contiennent au moins un peptide ou une protéine comportant au moins un déterminant antigénique d'un CTL d'une protéine VIH.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86070792A | 1992-03-31 | 1992-03-31 | |
US860,707 | 1992-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993019775A1 true WO1993019775A1 (fr) | 1993-10-14 |
Family
ID=25333839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/002978 WO1993019775A1 (fr) | 1992-03-31 | 1993-03-25 | Administration de liposomes contenant des peptides ou des proteines comportant des determinants antigeniques de ctl de proteines vih |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1993019775A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040243A1 (fr) * | 1995-06-07 | 1996-12-19 | U.S. Department Of The Army | Liposomes contenant une glycoproteide du virus de l'immunodeficience humaine et leurs procedes d'utilisation |
WO2000029008A2 (fr) * | 1998-11-16 | 2000-05-25 | Board Of Regents, The University Of Texas System | Induction de lymphocytes t specifiques du vih |
WO2000076537A2 (fr) * | 1997-09-10 | 2000-12-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilisation de complexes de peptide-lignee cellulaire semi-allogenique§ pour le traitement du cancer, du sida et d'autres maladies virales |
FR2806912A1 (fr) * | 2000-04-04 | 2001-10-05 | Fond Mondiale Rech Et Preventi | UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871488A (en) * | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
EP0339504A2 (fr) * | 1988-04-26 | 1989-11-02 | The Du Pont Merck Pharmaceutical Company | Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères |
WO1991004051A1 (fr) * | 1989-09-19 | 1991-04-04 | Medimmune, Inc. | Peptides comprenant des epitopes ctl de proteines hiv et leur utilisation |
US5030449A (en) * | 1988-07-21 | 1991-07-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthetic vaccine against AIDS virus |
-
1993
- 1993-03-25 WO PCT/US1993/002978 patent/WO1993019775A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871488A (en) * | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
EP0339504A2 (fr) * | 1988-04-26 | 1989-11-02 | The Du Pont Merck Pharmaceutical Company | Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères |
US5030449A (en) * | 1988-07-21 | 1991-07-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthetic vaccine against AIDS virus |
WO1991004051A1 (fr) * | 1989-09-19 | 1991-04-04 | Medimmune, Inc. | Peptides comprenant des epitopes ctl de proteines hiv et leur utilisation |
Non-Patent Citations (1)
Title |
---|
MOLECULAR IMMUNOLOGY, Volume 27, No. 6, issued 1990, NEURATH et al., "Confronting the Hypervariability of an Immunodominant Epitope Eliciting Virus Neutralizing Antibodies from the Envelope Glycoprotein of the Human Immunodeficiency Virus Type 1 (HIV-1)", pages 539-549. * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040243A1 (fr) * | 1995-06-07 | 1996-12-19 | U.S. Department Of The Army | Liposomes contenant une glycoproteide du virus de l'immunodeficience humaine et leurs procedes d'utilisation |
WO2000076537A2 (fr) * | 1997-09-10 | 2000-12-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilisation de complexes de peptide-lignee cellulaire semi-allogenique§ pour le traitement du cancer, du sida et d'autres maladies virales |
WO2000076537A3 (fr) * | 1997-09-10 | 2001-05-03 | Us Health | Utilisation de complexes de peptide-lignee cellulaire semi-allogenique§ pour le traitement du cancer, du sida et d'autres maladies virales |
WO2000029008A2 (fr) * | 1998-11-16 | 2000-05-25 | Board Of Regents, The University Of Texas System | Induction de lymphocytes t specifiques du vih |
WO2000029008A3 (fr) * | 1998-11-17 | 2000-08-10 | Univ Texas | Induction de lymphocytes t specifiques du vih |
US6656471B1 (en) | 1998-11-17 | 2003-12-02 | Board Of Regents, The University Of Texas System | HIV-specific T-cell induction |
US7306804B2 (en) | 1998-11-17 | 2007-12-11 | Board Of Regents, The University Of Texas System | HIV-specific T-cell induction |
FR2806912A1 (fr) * | 2000-04-04 | 2001-10-05 | Fond Mondiale Rech Et Preventi | UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8110203B2 (en) | Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes | |
AU2007202739B2 (en) | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV | |
US7172761B2 (en) | Polyvalent immunogen | |
US7195768B2 (en) | Polyvalent immunogen | |
WO1993022343A1 (fr) | Systeme antigenique a plusieurs peptides possedant des proprietes d'adjuvant, vaccins prepares a partir dudit systeme | |
AU2001282706A1 (en) | HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines | |
JP2003529319A (ja) | HIV−1gp41を標的化する広範に中和する抗体を誘発する方法 | |
JPH10504018A (ja) | ヘテロダイマーポリペプチド免疫原キャリア組成物および方法 | |
AU7467991A (en) | Synthetic polypeptides | |
JPH11515006A (ja) | ヒト免疫不全ウイルス感染の予防用合成ワクチン | |
Robinson et al. | Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells. | |
JPH10212300A (ja) | ペプチドワクチン | |
WO1993019775A1 (fr) | Administration de liposomes contenant des peptides ou des proteines comportant des determinants antigeniques de ctl de proteines vih | |
AU748700B2 (en) | HIV virus mimotopes | |
AU2006200454B2 (en) | Compositions and methods for treating viral infections | |
CA2035576A1 (fr) | Determinants antigeniques de forme de la glycoproteine gp 120 hiv-1 de l'enveloppe du virus l'immunodeficience humaine | |
WO1996040243A1 (fr) | Liposomes contenant une glycoproteide du virus de l'immunodeficience humaine et leurs procedes d'utilisation | |
KR100326938B1 (ko) | 지방산이 결합된 합성 펩타이드를 인지질 막에 재조합하여 제조한 조합물 및 그 제조방법 | |
AU2008203501A1 (en) | Compositions and methods for treating viral infections | |
AU2006200455A1 (en) | Compositions and methods for treating viral infections | |
MXPA00009831A (es) | Respuestas de celula t citotoxica especifica para vih |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |